Name: Yale Psychiatry Grand Rounds: February 4, 2022
Uploaded: 2022-02-04T16:46:08.51Z
Duration: 59 min 32 s
Description: "Addressing the Epidemic of Alzheimer's Dementia With Population Health Informed Collaborative Models of Care" Brent Forester, MD , Chief, Division of Geriatric Psychiatry, McLean Hospital

Yale Psychiatry Grand Rounds: February 4, 2022

February 04, 2022

"Addressing the Epidemic of Alzheimer's Dementia With Population Health Informed Collaborative Models of Care"

Brent Forester, MD, Chief, Division of Geriatric Psychiatry, McLean Hospital

Information

ID: 7414
To Cite: DCA Citation Guide

Download Transcript

00:00I'm Chris Van **** and I direct
00:04our department's division of
00:07aging and geriatric psychiatry.
00:09This is the first grand rounds that
00:12our division has hosted in some time
00:15and I I'd like to say I think we're
00:18resuming in very fine style with
00:20today's speaker doctor Brent Forrester.
00:23Now Brent is the chief of the division
00:25of Geriatric Psychiatry at McLean and
00:28Medical Director for Dementia care
00:30and behavioral and mental health.
00:32Population health management
00:34at Mass General Brigham.
00:38He is associate professor of psychiatry
00:40at Harvard Medical School and has
00:42several other titles that I won't list.
00:45But of special note is that Brent is
00:48the current president of the American
00:51Association for Geriatric Psychiatry,
00:54which is our national organization.
00:57He specializes in the treatment
00:59of older adults with depression,
01:01bipolar disorder,
01:03and behavioral complications of
01:05Alzheimer's disease and related dementia.
01:09As we'll see.
01:11In his presentation today,
01:13his research focuses on novel treatment
01:16approaches to manage the disabling
01:19behavioral complications of dementia
01:21such as agitation and aggression,
01:23and his presentation today is entitled
01:27addressing the epidemic of Alzheimer's
01:29dementia with evidence based approaches
01:32to treating Neuro psychiatric syndrome,
01:34symptoms of dementia,
01:36and population health informed
01:39collaborative models of care.
01:41So with no further delay,
01:43let me introduce to you
01:45doctor Brent Forrester.
01:48Thank you Chris for that kind
01:50introduction and really great to see
01:52many of you on the screen who I know
01:54who have been friends and colleagues
01:55of mine for quite so many years.
01:57I will say that Yale holds a special
01:59place in my heart because as Michelle
02:01and Kirsten know during the annual
02:04meeting I become A at least a
02:06member of your family by going out
02:07to a dinner with the Yale folks.
02:09So that's always a highlight
02:11of the year for me,
02:12and it's a real pleasure to
02:14speak to you today about a topic
02:15that's dear to my heart.
02:16Which is Alzheimer's disease?
02:18So I'm going to share my screen.
02:33And Chris, give me the
02:35thumbs up if that looks good.
02:37That looks good, alright, excellent.
02:39Alright, by the way,
02:41I should say the building on the left,
02:45the old print there is the original
02:47campus of the McLean Asylum and well,
02:49it says Somerville Mass.
02:50Some people would have call it now.
02:52Charleston Charles Charlestown,
02:53Massachusetts when it was founded in 1811,
02:56it moved to the campus where currently
02:58is in Belmont in 1895 and the buildings
03:01still pretty much look the same
03:03and and the building on the right,
03:05which little fuzzy is a new corporate
03:07structure that mass general Brigham
03:08built a few years ago and has largely
03:10been empty for the past two years.
03:12Because of the pandemic.
03:14But it represents our transformation
03:16from siloed sort of singular
03:18hospitals to a system of care,
03:20and I'm I'm mentioning that now
03:22because I think it's relevant for
03:23the the second part of the talk,
03:25which is more on the population
03:26health side of things.
03:30Alright, so here are some of my disclosures.
03:34So I'm going to talk a bit about
03:35real quickly about epidemiology of
03:37dementia and talk about a case,
03:38really to highlight some of the key
03:40clinical issues I want to address today,
03:41which are really the behavioral symptoms
03:43of dementia that drive the burden of
03:45this disease and give those of you,
03:46especially those of you who, whether you,
03:48whether your geriatric psychiatrist or not.
03:50Most people I realize or not you're going
03:53to be seeing not only an aging population,
03:55but you're going to be seeing an
03:57increasing aging population with
03:58various neurodegenerative illnesses
04:00including Alzheimer's disease.
04:01And knowing more about diagnosis
04:02and treatment approaches is going
04:04to become increasingly important,
04:05so that's what I really want to
04:07focus on today.
04:08And then I'll spend some time at the
04:09end talking about how we've adapted
04:11some of these key principles and
04:13implemented them in a population
04:14based setting in primary care.
04:18So I like to start every talk I give on
04:20Alzheimer's disease with the most recent
04:23facts and figures from the Alzheimer's
04:25Association and every March or so.
04:27So we're about to see another
04:28one of these in in about a month.
04:30The Alzheimer's Association comes
04:31up with their facts and figures
04:33that highlights demographic issues
04:35related to Alzheimer's disease.
04:36And I'll just highlight a few things on
04:38this slide right now in the United States,
04:40there are about 6.2 million
04:42Americans with Alzheimer's disease,
04:44and based on the aging of the population,
04:46that number is supposed to
04:47triple in the next 20 years.
04:48And that's not.
04:49Unique to the United States,
04:50it's true all over the
04:52world with aging adults.
04:54It's the 6th leading cause of death
04:55in the United States and by the way,
04:57the pandemic has been a disaster
04:59for Alzheimer's disease.
05:00The death rate in Alzheimer's dementia
05:01not only because of individuals who are in
05:04more advanced stages and congregate living,
05:06but but independently because of illness
05:09issues related to the illness of Alzheimer's,
05:11or the effect of the virus.
05:12We've seen just a much higher
05:15mortality rate over the past two years.
05:18This is a disease that not only
05:19impacts the person with the illness,
05:21but like many illnesses that we care for.
05:23In psychiatry really impacts the family.
05:25So we estimate there over 11.2 million
05:28Americans providing unpaid caregiving
05:30support to loved ones with dementia.
05:33The total cost of care in the United
05:35States in 2021 was $355 billion,
05:38with an added two $57 billion.
05:43For providing home care,
05:45for example, what's really important,
05:47I think that's become much more clear,
05:50especially in this report from the
05:522021 Alzheimer's Association report,
05:55was the bottom right box,
05:58which is really the disproportionate
06:00impact in underserved populations.
06:02And interestingly,
06:0336% of black Americans,
06:0618% of Hispanic Americans,
06:07in 19% of Asian Americans believe
06:09that discrimination is a barrier,
06:11or would be a barrier to receiving
06:13Alzheimer's care.
06:14And one of the biggest problems that
06:15we have in in the research setting.
06:17It's just ruin all of psychiatry.
06:18But we see this a lot in dementia as well.
06:20Is that we're seeing generally
06:23homogeneous populations being
06:24either volunteering for or being
06:26recruited into clinical trials,
06:28and so there's an increasing worry
06:29that what we're finding in some
06:31of these outcomes are really not
06:32representative of a larger population.
06:34So this is an area that I think
06:36throughout all of medicine,
06:37but but also here and Alzheimer's
06:39disease is a major issue.
06:41So let me start out by a relatively
06:43straightforward case of a gentleman
06:45that I saw a number of years ago,
06:46who at the time was in his late 60s and
06:49I had first seen him a few years earlier.
06:51When he presented with cognitive
06:53issues working as an accountant
06:55unable to do the tax returns and
06:57his partners were concerned,
06:59as was his wife,
07:00we diagnosed him with Alzheimer's
07:02dementia and now a few years
07:03later he had been having
07:04about two months of insomnia, irritability,
07:07physical restlessness and pacing,
07:08especially late in the day and for
07:10about the past week he started to talk
07:13to these imaginary people who were
07:14in his home and he started to look
07:16more confused according to his wife.
07:18He really had no major medical
07:20problems in the past.
07:21It was a very healthy guy.
07:23And we had put him a few years ago and
07:25and episil, or Aricept and Memantine.
07:26And Amanda standard treatments.
07:28Even today in 2022 for Alzheimer's disease.
07:31And he had been on mirtazapine for few years
07:34for anxiety and periods of insomnia as well.
07:37But now he was having some
07:38of these other symptoms.
07:39So what I want you to think about as
07:42we go through this talk is questions
07:44that come out of a case like this
07:46and how you would approach it.
07:48So for example, how?
07:49How would you define or describe
07:50these neuro psychiatric symptoms?
07:52Because they're they range
07:54across a spectrum of mood,
07:55anxiety, sleep,
07:56and then even into psychosis with paranoid
08:00delusions and possibly hallucinations.
08:02Most importantly,
08:03how would you seek the cause
08:04with the etiology of these neuro
08:06psychiatric symptoms and what?
08:07Medical or neurological diagnosis may
08:09help to explain this presentation.
08:12And if you're going to treat this individual,
08:15what target symptoms would you be
08:17going after and then what behavioral
08:19interventions might help and?
08:21And if you were going to use the medicine
08:22to augment treatment that he's currently on,
08:24what would you use and why?
08:25And what is the evidence based for that?
08:27So what I'm going to hopefully
08:28cover in this first part of the
08:30talk is really going through the
08:31systematic approach to assessment,
08:33diagnosis and then and then both
08:36behavioral and pharmacological
08:37management of these of these neuro
08:40psychiatric symptoms of dementia.
08:41So as far as background goes,
08:44if you see somebody with dementia
08:46over the course of their illness,
08:47neuro psychiatric symptoms
08:49are universally prevalent.
08:51In fact,
08:52some studies have shown rates of up
08:54to 100% over the course of illness.
08:56Again,
08:57they could be as mild as worrying or pacing,
08:59or they could be as severe
09:01as physical aggression.
09:02But when you see these symptoms,
09:03the reason they're important is not
09:05only they are disabling to the person
09:07and making them feel lousy and and
09:08concerned about safety concerns,
09:10but they do.
09:11Seem to be associated with a higher
09:13morbidity and even mortality,
09:14and a more rapid functional decline.
09:18Practice guidelines that exist,
09:20including the 2016 APA guidelines
09:22for the use of antipsychotics
09:24and Alzheimer's disease,
09:25recommend antipsychotics as first
09:27line treatment for those patients
09:29with dementia who have agitation
09:31that are associated with psychosis,
09:33so hallucinations or delusions.
09:34But what if you've got somebody who's
09:38physically aggressive or disinhibited
09:40verbally without any provocation,
09:42without any association with
09:44psychosis or or depression?
09:46That's where the even the experts don't
09:47agree on a first line of treatment.
09:49That's where we use combinations of
09:52medications that include antipsychotics
09:53or mood stabilizing
09:55anticonvulsants or SSRI's,
09:56and we'll talk more about this in detail.
09:58And so we have a number of
10:01different acronyms that are used
10:03to describe these syndromes,
10:04one of which is BPSD or the behavioral
10:06and psychological symptoms of dementia.
10:08But we don't have true standards of care.
10:10There is really no true
10:12algorithm or standards of care.
10:13Some have been developed,
10:14but it really has to be thought of
10:17on an individual patient level and
10:18and very importantly which a lot
10:20of people don't understand is that
10:22any drug ever used by any of us to
10:24treat these behavioral symptoms that
10:26dementia is by definition off label.
10:29Because the FDA has yet to approve
10:30a single drug to manage any
10:32behavioral symptoms of dementia,
10:33or the psychosis of dementia.
10:36So I mentioned these definitions,
10:38Dilip, Jeste,
10:39and Sandy Finkle came up with
10:41a psychosis avadi which was a
10:43diagnostic sort of a research
10:45diagnosis that was in the DSM 4
10:47neuro psychiatric symptoms of a D.
10:49This BPSD,
10:50but most importantly is that whatever
10:52the acronym is or the descriptor is,
10:55it's really important to go down into
10:57the nitty gritty and like what are
10:58the symptoms that person is presenting with,
11:00because these acronyms really account
11:02for a whole range of symptoms.
11:04As I mentioned before,
11:05and you can see here on the slide.
11:10The the most important really take
11:12home message from this part of the
11:14talk is that throwing medicines at
11:16patients who present with these symptoms
11:18without figuring out what's driving
11:20these symptoms will lead to problems.
11:22And it sounds so obvious to say.
11:24But when you're dealing with a
11:26fragile brain that's in the context
11:27of a neurodegenerative illness
11:29like Alzheimer's disease,
11:30the therapeutic index,
11:31the window for efficacy and
11:32tolerability is very, very narrow,
11:34and so if we're going to intervene
11:36with medications when appropriate,
11:37we've got to be very careful
11:39that we're actually.
11:39Now we're treating so the three big
11:41buckets of causes of these behavioral
11:44symptoms can be broken down into
11:46environmental precipitants like
11:47interactions with caregivers or time
11:49of day or change in routine or noise,
11:52or even cultural issues.
11:53The way in which a loved one will
11:55speak to their spouse with dementia
11:57and a person with dementia doesn't
11:59understand where they are or or or who
12:02their spouses and they start asking the
12:04same questions over and over again,
12:05and the spouse themselves is feeling
12:07exhausted and burned out and depressed.
12:09And before you know it.
12:09They're having arguments.
12:11Those things don't require necessarily
12:13medications, but a lot of caregivers,
12:14support education, etc.
12:17Medical causes in fact.
12:18The first,
12:19second and third things we look
12:21for when we see a patient like
12:23the one I described is might.
12:25May there be an infection or a new
12:27medication accounting for the side effect?
12:29Or maybe they're drinking
12:30alcohol or some other drugs.
12:31Or maybe they've got an electrolyte
12:33disturbance where their
12:34diabetes isn't well controlled,
12:35so that's what we're looking for in pain.
12:37And during the first wave of this pandemic,
12:40back in the winter of 2020,
12:43we saw a number of older
12:45patients presenting with.
12:47Delirium, agitation,
12:48confusion,
12:48etc superimposed on dementia as the
12:52first manifestation of COVID-19,
12:54which was very interesting.
12:55And we've we've seen and now know a
12:58lot more about the neuro psychiatric
12:59manifestations of this illness.
13:01And then finally, psychiatric.
13:02And the reason I bring this up is 2 fold.
13:05One is,
13:05it's really important to gather
13:07a pre-existing or prior to the
13:09onset of dementia.
13:10Psychiatric history from a family
13:12member or from some collateral source.
13:14Because what you might be seeing is
13:16somebody who's aging with bipolar
13:18disorder who's now got cognitive problems.
13:20Or you might be seeing somebody who
13:22never had a psychiatric problem and
13:24now now is experiencing Alzheimer's
13:25disease with superimpose behavioral
13:27complications and the approach to
13:29treatment may very well be different.
13:31I'll also tell you a little vignette here,
13:33because this story,
13:34which I this was a patient,
13:35I saw very early on in my career
13:37in a nursing home setting,
13:39taught me a lot about the importance of
13:41collateral information and diagnosis.
13:42So I was working at the mental
13:44Health Center of Greater Manchester,
13:46NH on the faculty at Dartmouth,
13:47and I was assigned to work in
13:49this nursing home and.
13:50One of the first days I
13:52actually worked in this
13:52nursing home, I was asked to see this woman.
13:55Who is 53 at the time and she was in a
13:57locked dementia unit and all I knew is
14:00that she had been hospitalized for a week
14:02before in the General Medical Hospital.
14:04After a syncopal episode at home was
14:06found to be dehydrated and and was
14:08admitted to the hospital and now she
14:10was diagnosed with picks disease or
14:12frontal temporal dementia variant and
14:14she wasn't cooperative with anything.
14:17She wasn't eating drinking,
14:19not cooperating with activities.
14:21So I saw her.
14:22She's standing in the hallway and
14:23she was first of all about 30
14:25years younger than everyone else.
14:26Which I thought was strange.
14:28I walked up to her and she had
14:30absolutely no facial expression.
14:32She was completely mute and when I
14:34went in the hallway to do a brief
14:37neurological exam on her and I did some
14:40assessment of upper extremity mobility.
14:42She left her hand up like this.
14:44She was catalepsy.
14:45I thought maybe you know this is unusual.
14:48Neurological manifestation of catatonia,
14:50but there's no psych history in her chart,
14:53so I called her husband and I said,
14:54Bob, what's going on with your wife?
14:56And he said, well,
14:57we've been married for 30 years,
14:58and she's got bipolar disorder,
14:59and she was doing pretty well
15:00until a few weeks ago, when she?
15:02Started but I thought was getting
15:04depressed and wasn't talking to us
15:05much and wasn't eating or drinking
15:07very well and she passed out one
15:09day and now they tell me she has
15:10end stage dementia and she's at
15:11the end of her life and I said,
15:13well you know Bob,
15:14it may be a manifestation of
15:15bipolar disorder we call catatonia,
15:17and so we had our hospitalized
15:20and she had ECT.
15:21And and she became my outpatient
15:22for the next five years because she
15:24went back to her normal baseline,
15:26which was essentially euthymic
15:28without catatonia,
15:29with some mild executive dysfunction
15:31and some delayed recall problems,
15:32which improved with prompting.
15:34But she certainly didn't have
15:36advanced frontal temporal dementia.
15:38I learned a lot from this case.
15:39One thing was which you read in
15:40a medical record is what you read
15:42in a medical record.
15:43And even with emr's these days,
15:44we know how those cannot be complete.
15:46It's not that they're wrong necessarily,
15:48but they're just not complete all the time,
15:50and there's really nothing that
15:51substitutes getting a really good
15:53history from a family member.
15:54And then finally,
15:55people with acute psychiatric
15:57illness like this woman had.
15:59It's impossible to know what their
16:01baseline cognitive functioning is.
16:02And until you treat that you
16:04don't really know what they're
16:06what the underlying baseline.
16:08A cognitive functioning maybe.
16:09So those are the three buckets of causes
16:11and keep that in mind as we go through
16:12some of the treatment approaches.
16:14So our colleagues,
16:15Helen Cals and others at the University
16:17of Michigan developed this dice approach,
16:19which was now published a few years ago
16:21in Jags. And this.
16:22This approach is really
16:23what I just told you about.
16:25It's like a it's just a systematic way
16:27of assessing describing the behavior
16:28you're seeing when it's happening,
16:30where what's provoking it,
16:32investigating the etiology,
16:33and you can see on the slide.
16:34There are many things,
16:36many of which I mentioned.
16:37Constipation, pain,
16:38medical problems, etc.
16:40And then create a treatment plan and that
16:42could be both behavioral and pharmacological.
16:44And very importantly,
16:45this is something we're not good at.
16:47In psychiatry is collecting
16:48objective data on symptom, severity,
16:51frequency and impact on caregivers,
16:53and then see how our treatment
16:55interventions actually impact outcomes.
16:57So there are a number of measures
16:58that we can use to assess
17:00behavioral symptoms in dementia.
17:01The one that's most widely
17:03used now in clinical trials.
17:05And we're trying to implement
17:06now in population settings,
17:07is the neuro psychiatric inventory.
17:09There's a version of it called the NPIQ,
17:11which is shorter, but it's burdensome.
17:14It takes a little time,
17:15but what's nice about the NPIQ is
17:17you're assessing 12 domains of behavior,
17:20mood, psychosis,
17:21etc,
17:22and the impact of this behavior
17:24on on the caregivers.
17:26Well being so that that is a
17:29really useful instrument.
17:30But implementing this in in
17:32traditional clinical care is
17:34is way easier said than done.
17:36This is not a talk where I'm
17:38going to go through an exhaustive
17:40series of studies on behavioral.
17:41You know interventions for or non
17:44pharmacological interventions
17:45for patients with dementia
17:47and behavioral symptoms,
17:48but I really want to call this out
17:50because before we intervene with
17:52medicines and let's unless it's an
17:53acute crisis with safety concerns,
17:55we need to intervene first
17:57with behavioral interventions,
17:59and those could be and the way I think
18:00about it is you've got to be creative.
18:02It's got to be individualized.
18:04Every study that's looked at this is said.
18:06It's not one size fits all.
18:07It's very.
18:07Individualized,
18:08and then if you look at the literature,
18:10you'll be disappointed because you'll see
18:12some studies that are not well designed.
18:14It's hard to have a control
18:16group and they're not that large,
18:17but they've been published
18:18in some good journals.
18:19Actually,
18:20the two areas that I really
18:23wanted to highlight here.
18:25Our are the activities and the exercise,
18:28so exercise,
18:29exercise and incredibly helpful
18:31intervention that might not only help
18:33us with our own brains as we age in
18:35terms of reducing the risk of Alzheimer's,
18:36but may also ameliorate some
18:38of the agitation anxiety that
18:41goes along with with dementia.
18:43And then there's the impact that
18:44you can have on caregivers because
18:46a lot of these precipitants to
18:49behavioral outbursts are often
18:50driven by the environment,
18:52which may be the caregivers,
18:53could be nurses and long.
18:54Long term care facilities nurses aides.
18:56It could be family members at home, etc.
18:58So,
18:58but there's a ton of need for
19:01good research in this area,
19:03and every guideline that you will
19:05read will say before you do anything
19:07with medicine you want to do non
19:09pharmacological interventions.
19:11So the the the next main part of this
19:13talk is really to focus on evidence
19:15based pharmacotherapy and then I'll
19:16talk a little bit about some of the work
19:18we're doing for some of the symptoms
19:20that are more difficult to treat.
19:22Now focus mostly here on the NSA koteks.
19:25And primarily because they're.
19:26They're the best studied.
19:28Frankly, class of drugs,
19:29and they're there's tremendous
19:31controversy with their use.
19:33It may be the most controversial thing
19:34that we have in geriatric psychiatry
19:36is that when to use and when not to
19:38use antipsychotics and older adults,
19:39but specifically in dementia.
19:40So I want to give you a sense of
19:43what the data shows first of all,
19:44with the limitations are what
19:45we can learn from it,
19:47how we apply it in clinical practice,
19:48and then the warnings that
19:50the FDA put out now in 2005.
19:51And I'll talk a little bit about some
19:53of the other classes in particular the.
19:55Antidepressants.
19:58So this is such a basic statement.
20:00I hate to mention it to this crowd,
20:01but it's something that happens
20:02all the time in psychiatry.
20:03You know, it's a Mrs.
20:04Jones has psychosis or the Mrs.
20:06Jones is psychotic.
20:06Well,
20:07what does that even mean?
20:08It's like saying where she has
20:09a psychotic disorder.
20:10It's like saying that Mrs.
20:11Jones has a cough disorder and it could be.
20:13It could be cancer,
20:14or you've got something stuck in your throat,
20:16or you've got an allergic reaction and
20:18the approach is totally different.
20:19So in older adults,
20:20although we may describe how someone
20:23is doing with a variety of symptoms,
20:25we've got to figure out the
20:27underlying diagnosis or we'll get
20:28lost very quickly with treatment.
20:30So we know what the diagnosis of
20:32psychosis is, but it it's a symptom.
20:33It's not a diagnosis,
20:35and in older adults who develop
20:37psychosis for the first time in
20:39their in in their later years,
20:41it's generally not late onset
20:43schizophrenia at the age of 70 or even
20:45late onset mania and bipolar disorder,
20:47it's usually dementia or it's
20:50delirium superimposed on dementia.
20:53And it may be the first manifestation
20:55of somebody with Alzheimer's disease.
20:57Not always,
20:57but it.
20:58It can be because you know half the
21:00people in the United States with
21:01dementia aren't diagnosed and the
21:03ones who are aren't diagnosed until
21:04they're already in the moderate stages,
21:06which is when you start to see psychosis,
21:09impaired memory from dementia is
21:11is often what is is the what,
21:15what the psychosis is really about,
21:16which is that they they can't remember
21:19where they are or they misidentify
21:21their spouse because they have.
21:23This, you know,
21:24Misidentification syndrome
21:25or Capgras syndrome,
21:27where they think they're like their
21:29caregivers an impostor or their mates,
21:31unfaithful,
21:31which the first patient that
21:34Doctor Alzheimer's saw Augusti.
21:35She actually believed that her
21:37made her spouse was unfaithful.
21:39That was one of her presenting symptoms so,
21:41but if you look at these quote
21:43unquote delusions,
21:44fixed false beliefs,
21:45they're often based on the fact
21:46that the persons having cognitive
21:48impairment and inability to recognize
21:50familiar people or things and then
21:52stories get created around it.
21:54So that's really important to keep in mind,
21:56and then finally the duration of
21:58treatment is often informed by the
22:00actual diagnosis and what I mean by
22:02that is if if this is delusions and
22:04Alisa nations and somebody who's
22:05manic with a history of bipolar
22:07disorder who also now later life,
22:08happens that dementia.
22:09You know they're going to need to
22:11continue to stay on pharmacotherapy,
22:13but if this is somebody with
22:14Alzheimer's disease and all of a
22:15sudden has a UTI and in the setting
22:17of the UTI they see things that
22:18aren't there and get agitated, well,
22:19you can give them a land subpoena or
22:22QT and perhaps a risperidone for a
22:24period of time because they're agitated.
22:26But if you don't treat their
22:28UTI without antibiotics,
22:29you're not going to get very far.
22:30So anyway, it it sounds so obvious,
22:33but this is what I mean about
22:35looking for the underlying cause.
22:38So the older drugs the conventional
22:40antipsychotics like caliper,
22:41it all are still used,
22:42hopefully rarely and there is data on them.
22:45But the reason why we don't use
22:47them much if at all is because of
22:50the toxic side effects and they
22:51really include extrapyramidal side
22:53effects like that are listed here.
22:55Risk of falls orthostasis with a low
22:58potency and psychotics and then the
23:01risk of tardive dyskinesia which.
23:03The risk factors for developing
23:05tardive dyskinesia as you all know,
23:07include advancing age,
23:08and so if you see somebody with
23:10schizophrenia in their 30s and they're
23:13treated with antipsychotic medication,
23:15the risk of developing TD in
23:17the first year is about 5%,
23:19and so about 5% every year.
23:20So after three years, it's about 15%.
23:22Now if that same person in their 70s,
23:25and you give them haloperidol for a year,
23:27it's 28% risk of TD,
23:30and that goes up to nearly
23:312/3 after three years.
23:32So that's one of the main reasons why.
23:34We really try to avoid these,
23:36especially for long term use in older adults.
23:40So I'm not going to go through the
23:42exhaustive literature on the atypical
23:43antipsychotic use in dementia,
23:44but I want to highlight that
23:46these four drugs, risperidone,
23:47olanzapine, Katipunan, aripiprazole.
23:49The reason why there's dosing
23:52ranges listed on the slide is
23:54because it's based on evidence.
23:56It's not just clinical judgment.
23:59There are a lot of studies that were done and
24:01will go through a few examples in a minute,
24:03but risperidone .5 to two?
24:04You'll notice these general doses are low.
24:07You'll notice the quote
24:08typing dose is quite variable,
24:09which is.
24:10One of the challenges with this
24:11drug is how hard it is to figure
24:13out what dose the person needs.
24:15There are a lot of other atypicals
24:16that have come on the market
24:18in the last decade or so with
24:19very little data and clozapine,
24:21which is a much older.
24:22Drugs still has very little data in dementia.
24:24There's a one positive and one negative
24:27brexpiprazole study with the third
24:29trial ongoing and pimavanserin which
24:31was being studied for the psychosis
24:34of or dementia related psychosis.
24:36In April of 2021,
24:39the FDA rejected their application.
24:40So there's more work going on there.
24:43Still to this day no drugs
24:45have been approved by the FDA.
24:47For the psychosis of
24:49Alzheimer's disease now TD,
24:50tardive dyskinesia does not go away
24:52when using an atypical antipsychotic,
24:54but it is much less than in
24:56the older adult population.
24:58On haloperidol, for example.
24:59So it's about 5% or so per year for
25:03risperidone and olanzapine compared
25:05to 28% with the conventional agents.
25:10I want to show you two
25:12studies only two studies,
25:13'cause this is a huge literature,
25:15but they highlight the way in
25:17which this data was collected and
25:20it's really important to remember.
25:23Generalizability of data.
25:24So the first series of studies
25:26that were done essentially in
25:28the 90s in the early 2000s.
25:30We're done in patients who were in
25:33nursing homes who had more advanced
25:35dementia with mini mental status exams
25:37in the single digits or low teens.
25:39Many of them had substantial
25:42medical comorbidity and some
25:44of them had mixed dementias,
25:45not just Alzheimer's disease,
25:47that they already had strokes
25:48and had vascular dementia.
25:50I mentioned that because of some of
25:51the problems with with mortality and
25:53stroke that I'll mention in a minute,
25:55so this was the risperidone trial.
25:56This was the first one published now.
25:59Crazy, it was back in 1999 already,
26:01but there were four different treatment arms,
26:04placebo .51 and two and one of the
26:06primary outcome measures that we looked
26:08at was the psychosis subscale of this
26:11behavioral measure in Alzheimer's disease.
26:14And what they found Ihracat still have
26:16Jesse and Jacobo Mintzer in this study.
26:19Was that once you got to a milligram a
26:21day you saw an improvement in psychosis,
26:24although the effect was modest.
26:26But once you went from one to two,
26:27you got no added benefit
26:30on reducing psychosis.
26:31Instead, what you got was doubling the
26:33rate of extrapyramidal side effects,
26:35and So what you see very clearly
26:36from this study,
26:37which was one of the five
26:39risperidone studies done.
26:40Again, advanced population,
26:41long term care settings,
26:43medical comorbidity.
26:44So if you saw somebody who's younger who's
26:46an outpatient who had a mini mental of 25,
26:48which you still see the same
26:49problems you know we,
26:50we don't have that data as much.
26:54But in the in these studies you
26:55see a lot of extra mental side
26:57effects once you go above 1,
26:58where between one and two this happens.
27:00I'm not sure you have to treat
27:02the individual, of course,
27:03but you're going to see rigidity and
27:05tremor and gait disturbance and so forth.
27:07Once you get above 1,
27:08certainly to 2 milligrams with risperidone.
27:11So there's a little bit of
27:12a therapeutic window there.
27:16Now I want to contrast that kind of study
27:18funded by the Pharmaceutical industry in
27:20the advanced patients and nursing homes.
27:22With the Katie study, most people who
27:24are not geriatric psychiatrist know about
27:26the Katie study because of schizophrenia.
27:29But there happened to be a sister study done
27:31at the same time called Katie Adie and that
27:34was the Alzheimer's sister study of Katie.
27:37And we were involved when I was up
27:39at Dartmouth back in the late 90s.
27:40In this trial we were one of the sites
27:42and it was 42 sites around the country.
27:44It was 421 patients but they were out
27:47patients including assisted living residents
27:48and they had a deal with either psychosis,
27:51aggression or agitation.
27:52Oh, and one thing I didn't mention was
27:54those first studies were only about 6
27:56to 12 weeks interation. These study.
27:59This study was 36 weeks in duration 9 months.
28:02And the individuals in this study
28:04were randomized to one of four arms,
28:06olanzapine, quetiapine, and risperidone,
28:08or placebo and the doses.
28:11The mean dose was based on the dose
28:13at the time that the person was
28:15switched from phase one to phase two.
28:18The way the study was designed is
28:20people were randomized to one of these
28:22four treatment arms and they were
28:24out patients if they had persistent
28:26psychosis and agitation the the
28:27investigators doing the study.
28:29The clinicians,
28:29like I was were really pretty quick.
28:33To switch because we knew that
28:3525% chance they were on placebo
28:37and they were outpatients,
28:38they were safety concerns,
28:39so the doses they got too.
28:40As you can see from the previous slide,
28:43a mean of five of alanza pain is therapeutic,
28:45at least in those earlier studies with
28:47risperidone being a milligram a day.
28:49Also therapeutic in QT app in the
28:52one quetiapine study that showed
28:54efficacy was 200 milligrams a day
28:56and and this may have been under
28:58dosed and then there's placebo.
29:00So at the end of the day the outcome
29:02that they looked at in this study.
29:03It was not symptom reduction.
29:05It was not reduction of psychosis
29:07or aggression on a rating scale.
29:09The outcome they looked at was how
29:10long did it take for the investigator
29:13to make a decision to switch from
29:15drug drug atede rugby and that
29:16decision is of course a balance
29:18of is the drug working or is the
29:20drug not being tolerated or not?
29:22So after the after looking at
29:24this as the primary outcome,
29:26this this effectiveness measure,
29:27there was really no difference in any of
29:29the four groups in terms of time to switch,
29:32and the reason for that was although
29:34there may have been some efficacy
29:36advantages and symptom reduction
29:38tolerability for placebo is way better
29:40and and so if you looked at only
29:44efficacy which is symptom reduction,
29:46psychosis or agitation,
29:47you stayed on risperidone and olanzapine
29:49longer than you did quit typing,
29:51which may have been underdosed or placebo.
29:54So the secondary outcomes were positive,
29:56but but not the primary outcome here.
29:58So when this came out,
29:59by the way which is now 16 years ago,
30:01it's made front page news and the
30:03question was do these drugs even work?
30:05But again, I think it's is this.
30:06It's an efficacy effectiveness difference.
30:11And as I mentioned before,
30:12the tolerability was the issue is
30:14that you know placebo was less often
30:16discontinued because of adverse events.
30:18What's interesting here is that and again,
30:20remember, it's only 421 patients,
30:22but there was no stroke difference.
30:23There was no death difference.
30:25There was no fall difference between these,
30:28you know drugs or or or placebo.
30:32Now Dev Dev Anand is a Colombian colleagues,
30:35tried to answer really important question
30:36a few years ago in this study which is
30:39like if you put somebody on risperidone,
30:40let's say and they've got psychosis
30:43and agitation in dementia.
30:44How long do you keep him on the drug?
30:46You know,
30:46when can you safely stop the drug
30:48and so the the way this study was
30:51designed is they they gave patients
30:5316 weeks of open label risperidone.
30:55And 180 were then randomized to staying
30:58on risperidone or or converting to
31:00placebo tapered off and going on placebo
31:02and what they found is that the relapse
31:05rates after four months of being on
31:07risperidone and now being stable.
31:08If you then take people off the
31:10relapse rates are twice as high and
31:12the next four months on placebo
31:14and then even higher three times
31:16as high over the next four months.
31:19So although all recommendations
31:20including the API guidelines I'm going
31:23to show you in a minute say after.
31:25A period of time attempt to taper
31:28and discontinue the medication.
31:30This was in the New England
31:31Journal of Medicine.
31:31It was a well designed study.
31:32It's it's easier said than done,
31:34so this is a challenge that we have.
31:37So I want to highlight some of the
31:39warnings so when risperidone was
31:41trying to convince the FDA back in the
31:43early 2000s that their drug may may
31:45have safety and efficacy advantages
31:46in this population and they went
31:48to the FDA for approval review.
31:50That's when they first noticed that
31:53there might be a stroke risk issue.
31:55There was one study that showed a
31:56higher risk of stroke like events
31:58and drug versus placebo.
31:59It led to an investigation of
32:01mortality in the in the warning.
32:03So if you just look at the stroke risk OK,
32:05these could be large hemorrhagic,
32:07or embolic strokes.
32:08It could be microvascular ischemic disease
32:10that that caused symptoms like dizziness,
32:13Tia like symptoms.
32:15The the risk of these stroke like
32:18events in drug versus placebo was two
32:20to three fold higher for risperidone,
32:23olanzapine and aripiprazole.
32:25Interestingly, not for quetiapine in fact,
32:28you might even argue that placebo
32:31was worse than than putting in
32:33terms of these risk factors,
32:34but the end was much smaller with
32:36with quote type you know overall
32:38than the others and this is not
32:40a black box warning from the
32:41FDA. This is a warning that's been placed
32:44on some of these atypical antipsychotics.
32:46But not all. This is the problem.
32:49Is this box warning.
32:50This is where the controversy comes
32:52from and it's really important to
32:54understand where the data was from.
32:56This was 17 trials that the FDA reviewed
32:59now 17 years ago with over 5000 patients,
33:022/3 on drug, a third on placebo,
33:05and these were patients who were
33:07studied in those original trials.
33:08Like I showed you with risperidone
33:10where these were end stage
33:11patients in nursing homes.
33:13Lominy mental scores,
33:14lots of medical comorbidity and the risk of
33:17death was four and a half percent on drug,
33:202.6% on placebo.
33:21So there's a higher statistically
33:22significant death. Great.
33:23And one of the big questions
33:25that people ask is, well,
33:26why were people dying on these
33:28drugs and and one of the,
33:29you know,
33:30we don't know for sure 'cause
33:31no autopsies were performed,
33:32but when you look at the cause of
33:34death that were documented by the
33:36clinicians overseeing the trials,
33:37it was either cardiac or infectious.
33:39And so one theory is that these
33:41drugs we know can prolong the QTC
33:43interval and it can cause cardiac
33:44arrhythmia and sudden cardiac death.
33:46So that could be 1 mechanism
33:48the other could be sedation,
33:51leading to aspiration, pneumonia,
33:52infection and and then subsequent deaths.
33:54So we don't know for sure.
33:56Those are two potential mechanisms.
33:58Interestingly,
33:58when the warning first came out in 05,
34:01it was just for the Atypicals,
34:03even though there were studies involving
34:05Haldol and conventional agents,
34:07but they weren't comparable studies,
34:08but they weren't these randomized
34:10well designed trials,
34:11and so eventually,
34:12though,
34:13in 2008,
34:13the FDA broadened the warning to
34:15include all NS psychotics and that's
34:17the warning that exists until today.
34:20So.
34:23Thankfully, our Appa came out with guidelines
34:26in 2016 and and those of us who serve on
34:29various committees at the APPA and AGP.
34:31We were able to inform or at least
34:33give some feedback on these guidelines.
34:35But I think the main the the main take
34:37home points that are on these guidelines
34:39are really what I just went over.
34:40You know, use these antipsychotics
34:42only if benefits outweigh risks.
34:44Start low and go slow.
34:45If there are adverse effects, continue
34:47to monitor risk and benefits of need.
34:51Really importantly, if no response
34:52after four weeks on an adequate dose,
34:55try something else,
34:56taper and discontinue,
34:57and then when there is an adequate response.
34:59If there is a controversial statement
35:01in any of these guidelines,
35:02it's probably this bullet point
35:04based on the Devon on study.
35:06Because if if if if you
35:08follow these guidelines,
35:09they would suggest no matter what tape the
35:11taper them off the drug after four months,
35:13unless you've had previous
35:14experience with a recurrence of
35:17symptoms that are problematic.
35:19And then again,
35:19avoid Haldol as a first line agent,
35:21because if you look at subsequent data,
35:23which really seem to show that
35:24the mortality risk is higher with
35:26the with the conventional agents,
35:28how paradol seems to have a higher
35:30mortality rate than than the atypicals
35:31that we want to avoid haloperidol and
35:33then there's really no data with long
35:35acting injectables in this population.
35:38So what are we supposed to do?
35:40One thing I'll just mention,
35:42which is not.
35:42I don't think I have a slide on this,
35:44but it's important to know is
35:45that these drugs?
35:46These antipsychotic drugs and frank
35:48and in fact all psychiatric drugs,
35:50are heavily regulated by the federal
35:53government in nursing homes in
35:55federally funded nursing homes.
35:56Because of Medicare and Medicaid,
35:58seems highly regulates the use of
35:59these drugs in those facilities.
36:01When can you start? How do you monitor?
36:04What do you have to document, etc.
36:07But the same patient with the
36:08same problems who happens to live
36:10in assisted living or at home.
36:11We can do whatever we want,
36:13so there's got to be a balance between
36:15over regulation and no regulation,
36:17because we do see misuse of these
36:19medications all the time when the
36:21warning first came out in 05,
36:23a lot of our colleagues in nursing home
36:25settings who were non psychiatrists
36:27said well for medical legal reasons,
36:29well, it's avoid alanza Pean.
36:31Let's put them on Ativan instead.
36:33Well,
36:33that's not a good idea because
36:35of tolerability issues.
36:35We'll talk more about in a minute.
36:37And I just say go back to the basics
36:39like we talked about what's causing
36:40these problems in the 1st place.
36:42Always employ these behavioral
36:44interventions first,
36:45and then if we're going to
36:46use antipsychotics,
36:47which sometimes are indicated,
36:49do it with informed consent,
36:51and I've never had a family member say to me.
36:53Well,
36:53don't treat my mom who's wandering
36:55into the street at night because she
36:57sees things outside or she's worried
36:59about people talking behind her back.
37:01But within antipsychotic,
37:01because it may lead to a small risk of
37:04death or mortality when there are safety
37:06issues concerned and the families are.
37:08Caring for their loved ones,
37:09they understand the risk benefit equation,
37:11but we've got to give informed consent.
37:15So that's probably more than you
37:17wanted to know about antipsychotics,
37:18Deppe code or dival proex was
37:20studied in at least four well
37:23designed randomized control trials.
37:24In many case series,
37:26there is evidence for reduction of agitation,
37:29but for whatever reason in in three
37:31of the trials there was no benefit
37:34on the primary outcome measure,
37:35but there was some benefit on a secondary
37:38and then in this ADC S trial which was done,
37:41there was no benefit on any measure.
37:43So since that trial came out,
37:45there's been less use of.
37:46Divalproex,
37:46one of the other issues is tolerability
37:49with gate disturbance tremor,
37:51even delirium.
37:52Some have been using gabapentin
37:54without almost any data,
37:56and there's some interest in doing an
37:59actual randomized trial with gabapentin
38:00because of its anxiolytic and effects.
38:02Perhaps on behavioral disinhibition,
38:04but there really is limited data.
38:07There's good data with the rise
38:09and our colleagues at Hopkins in
38:11Rochester and elsewhere collaborated
38:12on this Itala PRAM trial and
38:15agitation and Alzheimer's disease.
38:17I want to make the important
38:18point that this is for agitation
38:20and also arm is not depression.
38:22Almost all of the antidepressant
38:24trials for depression and dementia
38:26have not been positive trials.
38:28But this one, the sital Apram study,
38:30was for agitation,
38:31a dosing range of 10 to 30 milligrams a day.
38:33The behavioral effects were noted,
38:36and the thing we have to watch out for
38:37in the elderly is the QTC prolongation.
38:39Above 20 milligrams a day,
38:41this is with sital apram.
38:43There's now an escitalopram study going on.
38:46This was called site at the
38:47next one is called S site AD,
38:49and so we'll see what that one shows.
38:51So let me tell you a little bit about
38:53our journey with novel therapeutics
38:54before I go into public health.
38:56So a number of years ago
38:58I was medical Director,
39:00an inpatient geriatric psychiatry unit,
39:0218 beds, all dementia,
39:05all behaviorally disturbed.
39:06All there for two to three
39:09weeks of acute treatment.
39:10And it was a really amazing experience
39:13actually and and still exists.
39:15Today.
39:15We had this woman who came
39:17in at the age of 67.
39:19She had been diagnosed by colleagues
39:20of mine at mass general a decade
39:22earlier with Alzheimer's disease.
39:23She was now 10 years into an illness.
39:25She was essentially minimally
39:27verbally responsive at this point.
39:29She had attribute on her MRI demonstrating
39:31consistency with Alzheimer's,
39:32dementia, and at home with her spouse.
39:34The problem wasn't her her profound
39:37cognitive impairment or lack of speech.
39:39It was physical aggression with her spouse.
39:41Her husband really was overwhelmed
39:42and she had had at that .12
39:45failed medication trials and she
39:46really was not able to go into a
39:48nursing home from that situation
39:49and he couldn't manage her anymore.
39:51So she came in the hospital.
39:54Her name was Louise,
39:56two months in and I tell you her
39:58name because her daughter has
39:59been very public with her story.
40:01So two months into her hospital
40:03course she was really not responding.
40:05We tried every imaginable medication.
40:07She had tolerability concerns
40:08or she didn't respond and my
40:10colleague who I was working with,
40:11Doctor Alex Stoyer, said, well,
40:13what about ECT, and I said, well,
40:15why would you treat somebody
40:16with advanced dementia with ECT?
40:18I mean already she's got cognitive problems.
40:20He's like.
40:21Well, it can't get much worse and
40:22really other than palliative sedation,
40:24I'm not sure we have many options.
40:26Here and there was a small literature at
40:28the time on the use of ECT for patients,
40:30again with refractory agitation.
40:31This was not depression and dementia.
40:33This was aggression and dementia.
40:36So with consent from the caregiver and from.
40:41Appropriate medical clearance with our team.
40:42We treated her with ECT.
40:45She had eight in patient
40:46bilateral treatments.
40:47The profound effect was
40:49remarkable with some evidence.
40:51After the third treatment and
40:52then pretty remarkable improvement
40:54after the 8th when she went home
40:56she was down to two medications,
40:57really only as a talip RAM at that time.
41:00And and what's amazing about this woman
41:03is that she was treated at McLean
41:05Hospital monthly with maintenance ECT.
41:07For the next 10 years.
41:10And then she passed away from
41:12metastatic cancer about six years ago.
41:14So the daughter,
41:16who was very much impacted by her
41:19mom's illness and then became
41:20a big advocate for Alzheimer's
41:21disease research and treatment,
41:23also helped to support our further study
41:26of this one thing I'll say about this case,
41:29which was also amazing is that it
41:31LED us to treat more people like her
41:33with ECT and then collect data on it.
41:36And so we published one study that
41:38was 16 patients retrospective chart
41:40review with very poor data other than us.
41:44Filling out a Pittsburgh agitation
41:46scale based on you know 3 physicians
41:49agreeing to how symptomatic patients were.
41:51And then we decided to collect more data,
41:52but.
41:54One of the questions that's come up is,
41:56well, what about quality of life?
41:57And so this was Louise when in her
41:59earlier days and Karen statement
42:01about her mom and she basically
42:03said that my mom was a petite 5
42:05foot three 115 pound terror winner,
42:07aggression reared, she was uncontrollable,
42:09her medicines were losing efficacy
42:10and it became so dangerous for our
42:12in home aide and my dad and I that
42:14we had no option but to place her at
42:16McLean Hospital on the inpatient unit.
42:18But from that very first, ECT.
42:19The medical teams my father and
42:21I were were rendered speechless.
42:23Walking down the hallway after
42:25that first treatment.
42:25She came at me like she
42:27used to win aggressive,
42:27but this time she reached her arms.
42:29Let's rub my cheek lovingly.
42:30Shanda smile from ear to ear.
42:33And tears rolled down my cheeks.
42:34Her agitation and aggression
42:36nearly disappeared.
42:37She went from 31 medicines to one.
42:39We brought her back home and were
42:40blessed with another 10 years with her.
42:42This gave my mother tremendous quality
42:44of life and quality of care and my
42:46father gave my father, his wife and
42:48me and my mother and without ECT.
42:49She would never have seen me get married.
42:51So Karen was very public about this.
42:53She was on NPR.
42:55She she helped us some.
42:57Like I mentioned with our grant.
43:00Alright, So what about the data?
43:02So we we then realized that the
43:04retrospective chart review is not enough.
43:06Let's try to collect some data that we
43:08could find from doing a prospective study,
43:11and we thought we'd be clever.
43:12We thought we would have two groups.
43:14We would not randomize people,
43:15but for those people who agreed to get ECT.
43:18They would get ECT.
43:19And for those who said no,
43:21we would just follow them naturalistically.
43:22And by the time we actually intervene
43:25with ECT everybody wanted ECT.
43:27So this was the scale that we used
43:29as the primary outcome measure the
43:32Cohen Mansfield agitation inventory.
43:34Patients were in the hospital on
43:35average of four weeks before the 1st
43:37ECT treatment and these were people who
43:39had failed multiple medicine trials.
43:41They had on average 9.4 treatments and
43:43we saw meaningful improvements again.
43:46Open label by the 3rd treatment
43:48that continued to improve through
43:50the 9th treatment.
43:51So we spent many years collecting
43:53data at multiple sites and putting
43:55together this amazing team and
43:57we now have a five year.
43:59R A1 funded in 2018 by the NIH,
44:02where we're randomizing people to to ECT,
44:05which is now right.
44:06Unilateral, brief,
44:07ultra pulse ECT versus simulated ECT,
44:09which is essentially everything
44:12but anesthesia.
44:13We take people down to the ECT suite.
44:16We keep them in a separate room.
44:17They get an Ivy.
44:18They get gel in their scalp
44:20but they do not get anesthesia.
44:22They're PRN.
44:23Medicines can be used in the treatment
44:25team is blind to their allocated group.
44:27This has been a labor of challenge.
44:31We have been having lots of difficulty
44:34with recruitment for a variety of reasons,
44:36not the least of which is this pandemic,
44:38but also it took a year to get an
44:42investigational device exemption
44:43from the FDA,
44:44but I can talk more about this
44:46in the Q&A at the same time I
44:48was working on this unit.
44:49We also were experimenting at the time
44:51with Dronabinol or Marinol because of
44:53its effects on CB1 and CB2 receptors,
44:56but in particular the CB1
44:57receptor that may mediate the
45:00anxiolytic effects of cannabinoids.
45:01And and so again,
45:02for those of you who are maybe
45:04in training and are thinking
45:06about a research career,
45:07the idea of coming up with really
45:10important clinical questions based on
45:11what you're seeing in front of you.
45:12Research questions that could be
45:14addressed through research is really,
45:15really guided by your clinical experience.
45:18So we started using dronabinol
45:19and we wound up publishing.
45:21You know a paper on 40 patients,
45:23but the the theory behind this,
45:25and this was a paper we just published
45:27summarizing some of the literature on
45:29cannabinoids for Alzheimer's disease.
45:30For agitation in particular,
45:32like why would cannabinoids work?
45:34So there's a whole bunch of
45:35mechanisms that are fascinating here,
45:37including neurotransmitter regulation,
45:38but there seems to be neuroprotective
45:40effects as well as reducing
45:43neuroinflammation and oxidative stress.
45:44May help its circadian rhythm disturbances,
45:47a variety of other conditions
45:48like pain and anxiety.
45:50And then of course there may be some
45:52beneficial effects on the vascular system.
45:54In that first study that we published,
45:56it was 40 in patients
45:58with dementia agitation.
45:59We treated them with the mean dose of
46:01TREN abanil up to 7 milligrams a day.
46:03So again we tried to get people
46:05to 10 milligrams a day,
46:06but on average they were on 7.
46:08The primary outcome measure was the PS.
46:11The Pittsburgh Agitation Scale,
46:12which is 4 items of physical
46:14and verbal agitation.
46:16And the side effects were sedation,
46:18delirium and again whether it was related,
46:20unrelated, unclear.
46:21So we use this data and my colleague
46:24Paul Rosenberg and I collaborated
46:26together to write a a narrow
46:28one which got funded in 2016,
46:30and so we're we have a no cost extension.
46:32We're in now.
46:34And we're randomizing people
46:36to 5 milligrams a day for week.
46:38One of tRNA been all up to 10 milligrams
46:40a day. It's a three week trial.
46:43We started inpatient.
46:44We've now expanded to long term care
46:47and outpatient settings as well.
46:50We're looking at Alzheimer's
46:52disease predominantly and severe
46:54agitation using the IPA criteria.
46:56And we do have rescue medicines
46:58and we're allowing people to stay
46:59on their concomitant medications.
47:01And even with all of that,
47:02this is a very hard study to recruit for.
47:04But I guess the good news is we are now
47:07almost 60 patients into our our goal of 80.
47:10You can see our demographics here,
47:13weighted towards around 78 years old,
47:17about 65% women, which is pretty common.
47:19And like unfortunately,
47:20as I mentioned in the beginning,
47:21most of these studies,
47:23despite one of our sites being in
47:25Baltimore and one of our sites being
47:27in Miami where they have a very,
47:29very high Cuban American but
47:31essentially Latino population,
47:33we're still struggling with our
47:35demographics in terms of race and ethnicity.
47:38So hopefully we will have data on
47:40this within the next year or so.
47:42Finally, on the cannabinoid realm of things,
47:45my colleague at McLean, Stacy Gruber,
47:46and I have been collaborating together
47:48on a trial of cannabidiol CBD,
47:51mostly CBD.
47:51This is a plant based compound for
47:54anxiety in Alzheimer's disease,
47:56and again anxiolytic effects of this
47:59drug may be may be helpful specifically
48:02and may not induce psychosis like THC could,
48:07so this is a sublingual solution
48:09that is by weight,
48:11it's you know.
48:13.3% THC so it's predominantly
48:16CBD, 45 milligrams,
48:17with only a milligram of THC,
48:19and so we're now in them,
48:20and this is only an open label.
48:21Proof of concept Spiral Family
48:23Foundation funded study.
48:27So many reasons why not to use
48:30benzodiazepine's, the cholinesterase
48:31inhibitors and memantine do have some
48:34effects on anxiety and agitation.
48:36I'll just mention that the cholinesterase
48:39embitters may specifically address
48:41apathy and visual hallucinations and
48:43memantine may may also address agitation.
48:46But none of those effects are acute.
48:47You're not going to use these drugs and
48:50expect to see a response in a few days.
48:52So if you've got a patient who's mildly
48:54anxious and nonspecifically agitated,
48:56and by the way all of this presumes
48:58an adequate work up like we talked
49:00about and behavioral interventions.
49:01But if you've got a nonspecific
49:04agitation syndrome without aggression,
49:05without psychosis, without depression,
49:07based on the site at trial, you might.
49:10You might consider SSRI's, or,
49:12if they're not sleeping or eating well,
49:13mirtazapine, or if it's only intermittent,
49:16you might consider trazadone.
49:18If, on the other hand,
49:19there on the other side of the spectrum,
49:21they're physically aggressive and agitated.
49:23And they have psychosis.
49:24That's where the experts would agree
49:26that the atypical antipsychotics
49:27are a good first line of treatment.
49:29If they are aggressive and
49:31agitated with depression,
49:32again agitated and aggressive
49:34with depression,
49:35that's where you may want to
49:36start with S rise or rise,
49:37or even mirtazapine.
49:39But it's this fourth group that
49:41really is the challenging group.
49:42This is the group that I think
49:44winds up in hospitals difficult
49:45to treat in nursing homes.
49:47Why family members burnout?
49:48It's when you've got aggression
49:50without psychosis, we often will not.
49:51We don't really have a first line treatment.
49:54This is where we often use
49:56combination therapies,
49:57which may include anticonvulsants
49:59in atypical antipsychotics.
50:01Alright, so the last part of this talk.
50:05Before we do Q&A is I I wanna
50:07bring up the concept that we will
50:10never have enough specialists,
50:12not just in geriatric psychiatry,
50:13but in any psychiatry subspecialty
50:15to treat the mental health
50:17challenges of our population.
50:18And we all know this in our field and
50:20we're seeing it now highlighted by the
50:21pandemic in ways we couldn't have even
50:23imagined a few years ago in some ways.
50:25But some of what's driving the potential
50:27for optimism is really a transformation,
50:30and the way we organize health
50:32care and the way we pay for health
50:34care and so back in the old days,
50:36which is not that old and frankly,
50:38still dominates in many parts
50:39of the country we built,
50:41care around institutional settings,
50:43payments incentivized, more care.
50:45This is very true in our specialty arenas.
50:47You know, the more you do,
50:48the more you build, the more money you make.
50:52And again, this is often driven
50:54by procedural based specialties
50:55and in our old way of doing things
50:57and yesterday's healthcare system.
50:59Traditional fee for service Healthcare
51:00is really what this is is that we were
51:03responsible for getting people better
51:05now is immediate outcomes and we were
51:08grudgingly accepting and increasing costs
51:09which we no longer will do well with.
51:11The Affordable Care Act of 2010 and
51:14and population based approaches which
51:16have been taking hold in certain parts
51:18of the country with risk contracts
51:20where we're basically now being.
51:22Asked to build care around a patient,
51:25not around an institution,
51:27and instead of just trying
51:28to incentivize more care,
51:30we're incentivizing better care so that
51:33the reimbursement isn't just about volume,
51:35it's about value.
51:36It's about quality and addition to just,
51:38you know, doing,
51:39doing what you need to do and
51:41and we're not just responsible
51:42for how someone is doing today,
51:44but also over a longer period of time.
51:45And,
51:46and we're doing this in part because
51:47we just can't sustain the cost burden.
51:50These are the principles of value based care.
51:53And the triple aim of health care
51:55that Don Berwick talked about,
51:57which is trying to improve quality
51:59of care patient outcomes while
52:00reducing overall costs and a very
52:02important fourth part of the game,
52:04which is often not mentioned,
52:05which is our own quality of life, right?
52:07What about the health care?
52:09I mean,
52:09the mental health well being and
52:11the burnout in the health care
52:12providers which we're now seeing.
52:14Of course becoming tremendously challenged.
52:17And for those of you in geriatric psychiatry,
52:20I want you to know that there's a huge
52:22opportunity for us in this population.
52:24Health based landscape.
52:25And I would argue it's true
52:27for all of psychiatry.
52:29If anything value based care,
52:32I think has an opportunity to elevate
52:33psychiatry and to put us in a real
52:36leadership role in healthcare systems.
52:37Because if you really want to improve
52:40quality of life and reduce costs,
52:42you got to,
52:43you got to address mental health care
52:45and luckily we've got two decades of.
52:47Data suggesting that collaborative
52:49care approaches for depression in
52:51primary care incredibly effective,
52:53and we're now starting to see similar
52:55data in terms of Alzheimer's disease
52:57as one model for how geriatric
52:59mental health can be evolved or
53:02involved in a meaningful way in
53:04in this evolving landscape.
53:06This is a very busy slide,
53:08but I want to let you know that we're not
53:10the only ones that are doing this work.
53:12In mass General Brigham I would.
53:14I would point to two groups that
53:15have really three groups that
53:16have really led the way there.
53:18I would say anyone on this slide
53:19has really been leading the way,
53:20but David Rubin at UCLA geriatrician with
53:24his ADC program Alzheimer's Dementia
53:26Care and and the aging Braid Care program.
53:29Chris Callahan and Melos Boustani,
53:31all of these people are geriatricians
53:35and linking in with geriatric
53:36psychiatry is is they,
53:37they realize, is critical.
53:39UCSF developed the care ecosystem model
53:41in their memory and aging center,
53:43and then there are others as well.
53:44So there are a number of these programs
53:46that mind at home program at at Hopkins,
53:48for example, are trying to improve
53:51clinical outcomes like behavioral
53:52symptoms that dementia like caregiver
53:54stress while also reducing cost and
53:57doing it without the traditional,
53:59you know, 11 specialist doctor and one
54:01patient and family in a room together.
54:04So about three years ago we four years ago.
54:07Now we put together a bunch of experts
54:08across our health care system and we said,
54:10well, if we could do something
54:12for dimension primary care,
54:13what would it look like?
54:14How would we assess people who
54:15would be the target population?
54:17What would the model look like?
54:18We eventually decided to implement
54:20David Rubins UCLA model,
54:22which is seen here on the right
54:24side of the slide,
54:25which is pairing a dementia care
54:27manager who's a social worker with a
54:29geriatric NP and a supervising physician
54:32could be a geriatric psychiatrist.
54:33Could be a geriatrician.
54:34But someone who's expert in dementia care?
54:37The patient and the caregiver
54:39in the middle of this.
54:40Diagram and LinkedIn very closely
54:42with the primary care doc and
54:45using all available technology,
54:47including electronic records for developing
54:49registries and following people overtime.
54:51Our goal was to develop this high
54:53quality care program for individuals
54:55with cognitive impairment by
54:57facilitating evidence based assessment
54:59and treatment in primary care over
55:01the entire illness trajectory and for
55:03both the patient and their caregiver.
55:05So we targeted individuals who
55:07were members of our Medicare ACO.
55:10And had a known diagnosis of dementia
55:13based on codes in the EHR or were
55:15suspected to have cognitive impairment
55:18based on the clinician or family concern.
55:21And we have a whole series of
55:23services that we utilize and now
55:24that we've been doing this,
55:26we launched it timing wise about a month
55:28before the pandemic really took off.
55:31But this is essentially an
55:33embedded specialty care model.
55:35It's not very scalable, it's too costly.
55:38The outcomes that we're looking
55:39at now are promising David Rubins
55:41outcomes are very promising,
55:42but to scale it you actually have to
55:44do a lot of fee for service billing,
55:47using care management and E&M codes.
55:50Which is fine,
55:51but it's not going to be paid for alone
55:55by reducing the overall costs of care.
55:59So we then looked into other models
56:01and this is the UCSF model and we
56:03got a grant from the NIH impact
56:05Collaboratory couple years ago,
56:07and the idea here was to take the care
56:12ecosystem model developed at UCSF,
56:14which is originally implemented
56:15not with a nurse and social worker
56:18and and physician team,
56:20but with a health care navigator
56:22who's a non clinician who gets
56:24trained in basic dementia assessment.
56:27Two tools, one for the patient.
56:28For the caregiver and seven protocols
56:30that address the gold standard dementia.
56:33101 principles like medication
56:35deprescribing and reducing
56:36behavioral symptoms of
56:38dementia and supporting caregivers,
56:39and connecting people to
56:41resources and so forth.
56:42And so we decided.
56:44Instead of building a new
56:45siloed program in our system,
56:47we would take nurses who were part
56:49of our high risk care management
56:51program and we're following like
56:53180 patients on their caseload
56:55and we would train 20 of you know,
56:57train 15 nurses in our first
56:59wave and 15 in our second wave.
57:01But train them to manage in this
57:03evidence based way their dementia
57:05population on their care on their caseload,
57:08so maybe 10 or 15 of their
57:10180 would have dementia,
57:11so we're now in the midst of wave
57:13two and I would say my lesson
57:16learned from this is implementation
57:18is very very challenging.
57:19Nurses are overwhelmed with 180 very
57:21complex patients and even though
57:23they knew these dementia patients
57:25had been following them for years,
57:27we then asked them to do more
57:28than they would normally do,
57:30even though it's gold standard care.
57:32And they got quickly overwhelmed,
57:34so we're now trying to figure out
57:36ways to modify their caseload.
57:37So they can give these patients
57:39and caregivers the attention
57:40they need and deserve.
57:41But I do think and we'll be
57:43looking at our data soon it.
57:45I think this is a very interesting model,
57:47though that could potentially be
57:49scaled along with other resources.
57:51So just in summary.
57:54The behavioral symptoms that
57:55dementia part of this talk.
57:57It's really important to remember
57:58that these are symptoms.
57:59They're not diagnosis,
58:00they beg a need then to dig deep and
58:02find the underlying cause that's driving.
58:04The behavioral problem will
58:06always intervene no matter what.
58:07With these non pharmacological
58:09treatments and then,
58:10when needed,
58:11think about various evidence based
58:13pharmacotherapy strategies we
58:15talked about always monitoring,
58:17tolerability and and side effects
58:19and giving informed consent.
58:21At the end of the day,
58:22you know when you've got a really
58:23challenging patient like some
58:24of the ones that I mentioned.
58:25If you break it down to the basics of,
58:28you know what we're trying to do here.
58:29Our goals are pretty much
58:31always aligned with families.
58:32If we break it down to enhancing quality
58:34of life in keeping someone safe.
58:37And sometimes it's very complicated to
58:38figure out the right pathway forward,
58:40but that often will take a lot of
58:42the stress out of the room and
58:44allow people to develop a plan.
58:45And then finally there,
58:46there's going to be a lot more
58:48information about novel integrated
58:49care models, not just for dementia.
58:51But for all sorts of psychiatric
58:53care and primary care settings.
58:54I know many of you do this.
58:56I mean the VA, by the way,
58:57has been doing most of this than
58:58the rest of the health care systems
59:01because they essentially had these
59:03integrated care models going on
59:04way longer than the rest of
59:06traditional health care.
59:07But you're going to be seeing
59:08more and more of this,
59:09and I'm hopeful that it
59:11really allows those of us
59:12in psychiatry to really make a
59:14big impact and take a leadership
59:16role in caring for patients
59:17in primary care settings.
59:19So I'm going to stop there.
59:21And welcome any questions.
59:24So Brent first of all, let me just
59:28thank you for a wonderful talk.
59:30Couldn't couldn't thank you enough.